COMT and Parkinson disease: Previous studies have shown that combining LCIG infusion with an oral COMT inhibitor enables the dose of LCIG to be reduced by at least 20% while still maintaining stable levodopa concentrations and motor function.49, –51 These findings led to the development of LECIG infusion in which three established PD therapies – levodopa, the DDCI carbidopa and the COMT inhibitor entacapone – are combined in a single gel formulation, negating the need to take a separate oral COMT inhibitor.